Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 12/20 | 0.47 |
| ▸ | DRD2 | P14416 | 4/20 | 0.47 |
| ▸ | HTR2A | P28223 | 3/20 | 0.47 |
| ▸ | HTR7 | P34969 | 3/20 | 0.47 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | CA12 | O43570 | 3/20 | 0.43 |
| ▸ | CA2 | P00918 | 3/20 | 0.43 |
| ▸ | CA9 | Q16790 | 3/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | EGFR | P00533 | 4/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19054622 | 0.83 | HTR6 (0.53) | HTR6DRD2HTR2AHTR7HTR1A | |
| SCHEMBL29429815 | 0.80 | HTR6 (0.56) | HTR6DRD2HTR2AHTR7HTR1A | |
| SCHEMBL6039811 | 0.80 | HTR6 (0.56) | HTR6DRD2HTR2AHTR7HTR1A | |
| SCHEMBL16655060 | 0.80 | CDK7 (0.41) | HTR6DRD2HTR2AHTR7EGFR | |
| SCHEMBL19054640 | 0.78 | HTR6 (0.58) | HTR6DRD2HTR2AHTR7HTR1A | |
| SCHEMBL16655292 | 0.78 | CDK7 (0.48) | HTR6EGFR | |
| SCHEMBL20041265 | 0.77 | EGFR (0.43) | HTR6DRD2HTR2AHTR7HTR1A | |
| SCHEMBL18047405 | 0.77 | CDK7 (0.58) | — | |
| SCHEMBL17141074 | 0.76 | CCNT1 (0.49) | HTR6DRD2HTR2AHTR7EGFR | |
| SCHEMBL17140747 | 0.76 | CDK7 (0.52) | HTR6DRD2HTR2AHTR7HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190292167-A1 | HETEROAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | SYROS PHARMACEUTICALS INC (US) | 2019-09-26 | — | — | US | disclosed |
| US-20190292167-A1 | HETEROAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | SYROS PHARMACEUTICALS INC (US) | 2019-09-26 | — | — | US | disclosed |
| US-20160264552-A1 | HETEROMAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLFERATIVE DISEASES | SYROS PHARMACEUTICALS INC (US) | 2016-09-15 | — | — | US | disclosed |
| US-20160264552-A1 | HETEROMAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLFERATIVE DISEASES | SYROS PHARMACEUTICALS INC (US) | 2016-09-15 | — | — | US | disclosed |
| US-20160264552-A1 | HETEROMAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLFERATIVE DISEASES | SYROS PHARMACEUTICALS INC (US) | 2016-09-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190292167-A1 | HETEROAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES | CDK7, CDK3, CDK17 | HTR6 2975/4885DRD2 4726/4885HTR2A 4449/4885 |
| US-20160264552-A1 | HETEROMAROMATIC COMPOUNDS USEFUL FOR THE TREATMENT OF PROLFERATIVE DISEASES | CDK7, CDK6, CDK3 | HTR6 3045/4885DRD2 4814/4885HTR2A 4640/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.